COPD drug roflumilast tested as depression booster
NCT ID NCT06860958
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding roflumilast (a COPD drug) to the antidepressant fluoxetine helps people with major depression who haven't responded well to treatment. Sixty adults with moderate-to-severe depression will take either the combination or a placebo for 8 weeks. The main goal is to see if depression scores improve more with the added drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Roflumilast (a drug for COPD) combined with fluoxetine (an antidepressant)
- What this could lead to
- If it works, this could offer a new option for people with depression who don't get better with standard antidepressants alone.
- What could go wrong
- This is a small, early-phase trial with only 60 people. Roflumilast can cause nausea and vomiting, and it's not yet proven to help depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta Unuversity
RECRUITINGTanta, 31527, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a single dose of a new drug boost depression relief?
- Can a new pill ease depression without Add-Ons?
- Brain scans could make TMS for depression more precise
- Can brain training help depressed young adults stop ruminating?
- 45,000 students to be tracked: can we predict who will fall into depression?
- New depression pill BI 1569912 put to the test in 225-Person trial